These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38760553)

  • 1. FOXO1 enhances CAR T cell fitness and function.
    Marchal I
    Nat Biotechnol; 2024 May; 42(5):699. PubMed ID: 38760553
    [No Abstract]   [Full Text] [Related]  

  • 2. FOXO1 is a master regulator of memory programming in CAR T cells.
    Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
    Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
    Chan JD; Scheffler CM; Munoz I; Sek K; Lee JN; Huang YK; Yap KM; Saw NYL; Li J; Chen AXY; Chan CW; Derrick EB; Todd KL; Tong J; Dunbar PA; Li J; Hoang TX; de Menezes MN; Petley EV; Kim JS; Nguyen D; Leung PSK; So J; Deguit C; Zhu J; House IG; Kats LM; Scott AM; Solomon BJ; Harrison SJ; Oliaro J; Parish IA; Quinn KM; Neeson PJ; Slaney CY; Lai J; Beavis PA; Darcy PK
    Nature; 2024 May; 629(8010):201-210. PubMed ID: 38600376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cells Releasing IL-18 Convert to T-Bet
    Chmielewski M; Abken H
    Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
    Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
    JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
    Feucht J; Abou-El-Enein M
    Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
    [No Abstract]   [Full Text] [Related]  

  • 9. CD70 CAR T cells in AML: Form follows function.
    Mirazee J; Shah NN
    Cell Rep Med; 2022 May; 3(5):100639. PubMed ID: 35584621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T cells for solid tumors - developments to watch in 2023.
    Trefny MP; Kobold S
    Expert Opin Biol Ther; 2024 Apr; 24(4):207-211. PubMed ID: 38526025
    [No Abstract]   [Full Text] [Related]  

  • 11. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 12. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T cells take to the airways.
    Bordon Y
    Nat Rev Immunol; 2024 Jul; 24(7):457. PubMed ID: 38858573
    [No Abstract]   [Full Text] [Related]  

  • 14. The invisible hand: How epigenetics shapes CAR T cell destiny.
    Ali A; Zhang Y; DiPersio J
    Mol Ther; 2024 Jun; 32(6):1614-1616. PubMed ID: 38761798
    [No Abstract]   [Full Text] [Related]  

  • 15. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-cell therapy for solid tumours.
    The Lancet Oncology
    Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
    [No Abstract]   [Full Text] [Related]  

  • 17. FAS signalling pathway is crucial for CAR T cell persistence.
    Loves R; Grunebaum E
    Nat Rev Immunol; 2024 Jun; 24(6):380. PubMed ID: 38671171
    [No Abstract]   [Full Text] [Related]  

  • 18. [Application of mRNA nano-delivery system in CAR-T tumor immunotherapy].
    Zeng Y; Wei S; Sun J; Xu N
    Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1338-1351. PubMed ID: 38783801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future.
    Mougiakakos D
    Signal Transduct Target Ther; 2024 Oct; 9(1):276. PubMed ID: 39379353
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.